Luo et al. (2012) confirmed the effectiveness of kaempferol in lessening the chances of ovarian cancer. Their experimental analysis displayed that kaempferol impeded VEGF secretion in a timely manner via the ERK-NF-κB-cMyc-p21-VEGF pathway and repressed angiogenesis in vitro. Kaempferol decreases the relationship between ERK phosphorylation and expression of NF-κB and cMyc, but increases expression of p21 (Figure 4). The gene discussed is MYC; the disease is ovarian cancer.